Posted by Michael Wonder on 20 Jul 2022
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto
20 July 2022 - Oncopeptides today announces that the US FDA, has announced a forthcoming public advisory meeting of the Oncologic Drugs Advisory Committee on 22 September 2022 to discuss the benefit/risk of Pepaxto (melphalan flufenamide).
On January 21 2022, Oncopeptides announced that it has rescinded the 22 October 2021 letter requesting a voluntary withdrawal of the new drug application of Pepaxto in the US.
